RxDoctor Payments Data

Andrew Kerby, MD

Neurology · Corinth, MSNPI 1104844505

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 672 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.

$10,645in general payments, 2019–2025

Across 672 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Biogen$997
  • SK Life Science, Inc.$924
  • Teva Pharmaceuticals USA, Inc.$807
  • AbbVie$723
  • Pfizer$608
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$10,56899%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,645 in reported general payments places this provider in the 70th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$278,238
Medicare patients
633
Services billed
4,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine63$736,759
TysabriNatalizumab55$445,963
Kesimpta PenOfatumumab43$429,626
GammakedImmune Globul G/Gly/Iga Avg 4625$154,964
Nurtec OdtRimegepant Sulfate53$78,259
Aimovig AutoinjectorErenumab-Aooe27$27,336
Emgality PenGalcanezumab-Gnlm24$22,913
BriviactBrivaracetam13$17,504
Lamictal XrLamotrigine11$15,044
Ajovy AutoinjectorFremanezumab-Vfrm18$12,560
RytaryCarbidopa/Levodopa27$12,383
EliquisApixaban17$9,621
Levetiracetam429$9,356
Lacosamide132$9,138
Emgality SyringeGalcanezumab-Gnlm12$7,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt, Eliquis$608$824,639133 claims
BiogenTysabri$997$445,96355 claims
Kedrion Biopharma, Inc.Gammaked$16$154,96425 claims
UCB, Inc.Briviact$191$17,50413 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$547$13,36150 claims
Upsher-smith Laboratories LLCTopiramate$121$2,138146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 neurology providers in Mississippi.

Other neurology in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →